首页 > 市场调查报告书 > 医疗设备

医学影像诊断癌症个人化医学分子呈像/呈影剂核子医学

市场调查报告书

商品编码

1909170

治疗诊断学市场规模、份额及成长分析（依产品、技术、疾病、最终用户及地区划分）－2026-2033年产业预测

Theranostics Market Size, Share, and Growth Analysis, By Product, By Technology (Molecular Imaging, Radioligand Therapy), By Disease, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月02日 | 出版商:

SkyQuest | 英文 187 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球治疗诊断学市场规模将达到 25 亿美元，到 2025 年将达到 28.3 亿美元，到 2033 年将达到 78.1 亿美元，在预测期（2026-2033 年）内，复合年增长率将达到 13.5%。

全球治疗诊断学市场正经历强劲成长，这主要得益于人们对个人化医疗日益增长的需求以及包括癌症和心血管疾病在内的慢性病发病率的上升。这个创新领域将诊断和治疗功能整合于单一平台，有助于提高治疗效果并降低医疗成本。影像诊断技术的进步以及标靶药物递送生物标记的开发，正在拓展治疗诊断学在已开发经济体和新兴经济体的应用范围。然而，挑战依然存在，包括高昂的研发成本、复杂的法规环境以及低收入族群认知度不足。此外，有限的保险覆盖范围和对专用基础设施的需求也阻碍了治疗诊断学解决方案融入传统临床实践，凸显了政策改革和策略伙伴关係对于克服这些障碍的必要性。

全球治疗诊断学市场驱动因素

全球治疗诊断学市场成长的主要驱动力之一是个人化医疗的日益普及。这种方法强调根据个体的基因和分子特征量身定制治疗策略，将诊断和治疗流程结合。这种对个人化治疗的关注使医疗服务提供者能够在提高疗效的同时，最大限度地减少患者的副作用。这种向整合解决方案的转变不仅改善了治疗结果，还提高了患者照护的整体质量，因此个人化医疗成为治疗诊断学市场扩张的关键驱动力。

限制全球治疗诊断学市场发展的因素

全球治疗诊断学市场受到许多重大财务障碍的限制，影响了其可近性。先进成像技术、专用试剂和合格人员的高昂成本构成了复杂的成本结构。这种经济负担对医疗资源匮乏地区和农村地区的影响尤其严重，限制了他们获得治疗诊断学影像产品的机会。此外，这些成本还会加重医疗系统的负担，并使报销模式变得复杂。政治上的不确定性以及治疗诊断学解决方案融入标准临床实践的潜在延迟进一步加剧了这种情况，最终限制了市场成长和这些创新治疗方法的广泛应用。

全球治疗诊断学市场趋势

将人工智慧 (AI) 整合到诊断和治疗系统中是全球治疗诊断学市场的一大趋势。这种创新组合透过 AI 辅助诊断，有效调整治疗方案以适应个别患者，从而增强了个人化医疗。 AI 对临床、治疗和诊断数据的分析有助于高效解读医学影像，并提高治疗反应的预测准确性。因此，这一新兴领域不仅加速了精准医疗的发展，而且透过即时、数据驱动的策略，优先考虑患者疗效，从而推动复杂疾病的管理，在全球范围内改变着医疗保健模式。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Bayer AG
GE Healthcare
Siemens Healthineers
Thermo Fisher Scientific Inc.
Abbott Laboratories
Novartis AG
Telix Pharmaceuticals Limited
Curium Pharma
Advanced Accelerator Applications（AAA）
Bracco Imaging SpA
Lantheus Holdings
NanoString Technologies, Inc.
Roche Holding AG
Qiagen NV
Illumina Inc.
Myriad Genetics, Inc.
AbbVie Inc.
Philips Healthcare
Endocyte, Inc.
NorthStar Medical Radioisotopes LLC

结论与建议

简介目录

Product Code: SQMIG35G2362

Global Theranostics Market size was valued at USD 2.5 Billion in 2024 and is poised to grow from USD 2.83 Billion in 2025 to USD 7.81 Billion by 2033, growing at a CAGR of 13.5% during the forecast period (2026-2033).

The global theranostics market is experiencing robust growth driven by a rising demand for personalized medicine and the increasing prevalence of chronic diseases, including cancer and cardiovascular disorders. This innovative field, which combines diagnostic and therapeutic functions into a single platform, enhances treatment efficacy while fostering cost savings in healthcare. Advancements in imaging technologies and biomarkers for targeted drug delivery are broadening the scope of theranostic applications across both developed and emerging markets. However, the market faces challenges such as high development costs, complex regulatory environments, and limited awareness in low-income regions. Additionally, restricted reimbursement and the need for specialized infrastructure hinder the integration of theranostic solutions into conventional clinical practices, emphasizing the necessity for policy reforms and strategic partnerships to overcome these obstacles.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Theranostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Theranostics Market Segments Analysis

Global Theranostics Market is segmented by Product, Technology, Disease, End-User and region. Based on Product, the market is segmented into Diagnostic Imaging Agents, Radiopharmaceuticals & Targeted Therapeutics, IVD/Biomarker Screening Kits and Software & Services. Based on Technology, the market is segmented into Molecular Imaging (PET/SPECT), Radioligand Therapy, Nanoparticle-based Theranostics and Biomarker-driven Companion Diagnostics. Based on Disease, the market is segmented into Oncology, Neurology, Cardiovascular Diseases, Immunological/Inflammatory Disorders and Others. Based on End-User, the market is segmented into Hospitals & Cancer Treatment Centres, Diagnostic Laboratories, Research & Academic Institutes and Theranostics Centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Theranostics Market

A significant catalyst for growth in the global theranostics market is the increasing adoption of personalized medicine. This approach emphasizes tailored treatment strategies by combining diagnostic and therapeutic processes that align with individual genetic and molecular characteristics. By focusing on personalized therapies, healthcare providers can achieve enhanced therapeutic outcomes while minimizing adverse effects for patients. This shift towards integrated solutions not only improves treatment efficacy but also elevates the overall quality of patient care, making personalized medicine a key driving force behind the expansion of the theranostics market.

Restraints in the Global Theranostics Market

The Global Theranostics market is hindered by significant financial barriers that impact accessibility. The high expenses involved in acquiring advanced imaging technologies, specialized reagents, and qualified personnel create a challenging cost structure. This financial burden particularly affects underserved and rural regions, limiting their access to theranostic imaging products. Additionally, these costs can strain healthcare systems and complicate reimbursement models. Political uncertainties and the potential for delays in the integration of theranostic solutions into standard clinical practice further exacerbate the situation, ultimately restricting the market's growth and the widespread adoption of these innovative therapies.

Market Trends of the Global Theranostics Market

The global theranostics market is witnessing a significant trend driven by the integration of artificial intelligence into diagnostic and therapeutic systems. This innovative combination enhances personalized medicine by enabling AI-assisted diagnosis that tailors treatments to individual patients effectively. The AI-powered analysis of clinical, therapeutic, and diagnostic data facilitates the efficient interpretation of medical images and improves predictions regarding therapy responses. As a result, this burgeoning field is not only accelerating the evolution of precision medicine but also advancing the management of complex diseases through real-time, data-driven strategies that prioritize patient outcomes, thereby reshaping healthcare paradigms on a global scale.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Assessment
Regulatory Landscape

Global Theranostics Market Size by Product & CAGR (2026-2033)

Market Overview
Diagnostic Imaging Agents
Radiopharmaceuticals & Targeted Therapeutics
IVD/Biomarker Screening Kits
Software & Services

Global Theranostics Market Size by Technology & CAGR (2026-2033)

Market Overview
Molecular Imaging (PET/SPECT)
Radioligand Therapy
Nanoparticle-based Theranostics
Biomarker-driven Companion Diagnostics

Global Theranostics Market Size by Disease & CAGR (2026-2033)

Market Overview
Oncology
Neurology
Cardiovascular Diseases
Immunological/Inflammatory Disorders
Others

Global Theranostics Market Size by End-User & CAGR (2026-2033)

Market Overview
Hospitals & Cancer Treatment Centres
Diagnostic Laboratories
Research & Academic Institutes
Theranostics Centres

Global Theranostics Market Size & CAGR (2026-2033)

North America (Product, Technology, Disease, End-User)
- US
- Canada
Europe (Product, Technology, Disease, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Technology, Disease, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Technology, Disease, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Technology, Disease, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Telix Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curium Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advanced Accelerator Applications (AAA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bracco Imaging S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NanoString Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Philips Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Endocyte, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NorthStar Medical Radioisotopes LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments